Avanos Medical (AVNS) EBITDA Margin (2013 - 2026)

Avanos Medical has disclosed EBITDA Margin across 14 years of filings, most recently posting 4.88% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 4.88%, down 126.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.8% (up 4777.0% YoY), and the FY2025 annual result was 8.78%, up 4882.0% from the prior year.
• EBITDA Margin came in at 4.88% for Q1 2026 at Avanos Medical, up from 1.38% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 9.14% in Q4 2022 to a low of 233.02% in Q4 2024.
• The 5-year median for EBITDA Margin is 3.67% (2024), against an average of 13.0%.
• Across the five-year window, EBITDA Margin tumbled 23948 bps in 2024 and jumped 23440 bps in 2025, its largest moves.
• Avanos Medical's EBITDA Margin stood at 9.14% in 2022, then dropped by 29 bps to 6.46% in 2023, then tumbled by 3706 bps to 233.02% in 2024, then soared by 101 bps to 1.38% in 2025, then jumped by 253 bps to 4.88% in 2026.
• The last three EBITDA Margin figures came in at 4.88% (Q1 2026), 1.38% (Q4 2025), and 0.06% (Q3 2025), per Business Quant data.